CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition

Figure 5

MACS-sorted CD133(+) BAK melanoma cells are resistant to MAPK inhibitors. BAK cells were separated by MACS as shown in Figure 4. CD133(+) and CD133(-) BAK cells were then exposed to increasing concentrations MAPKI and cell viability assessed by XTT assays (a). IC50 was then calculated for each treatment group (b). Error bars represent mean ± SD for triplicates. Experiments were performed three times; a representative experiment is shown. Similar results were obtained following FACS sorting of BAK cells (Supplementary Figure s2) or MACS sorting of STU and BUL cells (Supplementary Figure s3).

(a)

(b)